Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
ST Renfu: The drug listing approval application for the holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd.'s Methylphenidate Hydrochloride Extended-Release Capsules has been accepted
ST Renfu Announcement, the holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. recently received the “Acceptance Notice” for the drug registration and market approval application of Methylphenidate Hydrochloride Extended-Release Capsules approved and issued by the National Medical Products Administration. Methylphenidate Hydrochloride Extended-Release Capsules are mainly used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 and above. As of now, Yichang Renfu has invested approximately 59 million yuan in research and development for this project.